MedTrace Logo

A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors

NCT07028268 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2025-12-31

No results posted yet for this study

Summary

The study is being conducted to evaluate the efficacy, and safety of SHR-2017 Injection in Patients with Bone Metastases from Solid Tumors. To explore the reasonable dosage of SHR-2017 Injection for Bone Metastases from Solid Tumors

Conditions

  • For Prevention of Bone Events in Patients With Bone Metastases From Solid Tumors

Interventions

DRUG

SHR-2017、Denosumab placebo

SHR-2017; high dose ；Denosumab placebo

DRUG

SHR-2017、Denosumab placebo

SHR-2017; low dose ；Denosumab placebo

DRUG

Denosumab；SHR-2017 placebo

Denosumab；SHR-2017 placebo

Sponsors & Collaborators

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-24
Primary Completion
2025-12-31
Completion
2027-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07028268 on ClinicalTrials.gov